



ORIGINAL ARTICLE

Sarcomeric hypertrophic cardiomyopathy: Genetic profile in a Portuguese population

Dulce Brito^{a,c,*}, Gabriel Miltenberger-Miltenyi^b, Sónia Vale Pereira^b,
Doroteia Silva^c, António Nunes Diogo^c, Hugo Madeira^a

^a Faculdade de Medicina de Lisboa, Centro de Cardiologia da Universidade de Lisboa (CCUL), Lisboa, Portugal

^b Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Lisboa, Portugal

^c Serviço de Cardiologia I, Centro Hospitalar de Lisboa Norte, E.P.E., Lisboa, Portugal

Received 5 December 2011; accepted 15 December 2011

Available online 2 August 2012

KEYWORDS

Sarcomeric hypertrophic cardiomyopathy;
Mutations;
Sarcomeric genes;
Prevalence;
Risk stratification

Abstract

Background: Sarcomeric hypertrophic cardiomyopathy has heterogeneous phenotypic expressions, of which sudden cardiac death is the most feared. A genetic diagnosis is essential to identify subjects at risk in each family. The spectrum of disease-causing mutations in the Portuguese population is unknown.

Methods: Seventy-seven unrelated probands with hypertrophic cardiomyopathy were systematically screened for mutations by PCR and sequencing of five sarcomeric genes: *MYBPC3*, *MYH7*, *TNNT2*, *TNNI3* and *MYL2*. Familial cosegregation analysis was performed in most patients.

Results: Thirty-four different mutations were identified in 41 (53%) index patients, 71% with familial hypertrophic cardiomyopathy. The most frequently involved gene was *MYBPC3* (66%) with 22 different mutations (8 novel) in 27 patients, followed by *MYH7* (22%), *TNNT2* (12%) and *TNNI3* (2.6%). In three patients (7%), two mutations were found in *MYBPC3* and/or *MYH7*. Additionally, 276 relatives were screened, leading to the identification of a mean of three other affected relatives for each pedigree with the familial form of the disease.

Conclusions: Disease-associated mutations were identified mostly in familial hypertrophic cardiomyopathy, corroborating the idea that rarely studied genes may be implicated in sporadic forms. Private mutations are the rule, *MYBPC3* being the most commonly involved gene. Mutations in *MYBPC3* and *MYH7* accounted for most cases of sarcomere-related disease. Multiple mutations in these genes may occur, which highlights the importance of screening both. The detection of novel mutations strongly suggests that all coding regions should be systematically screened. Genotyping in hypertrophic cardiomyopathy enables a more precise diagnosis of the disease, with implications for risk stratification and genetic counseling.

© 2011 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L. All rights reserved.

* Corresponding author.

E-mail addresses: dulcebrito@spc.pt, dulcebrito59@gmail.com (D. Brito).

PALAVRAS-CHAVE

Miocardiopatia hipertrófica sarcomérica; Mutações; Genes sarcoméricos; Prevalência; Estratificação do risco

Miocardiopatia hipertrófica sarcomérica: perfil genético numa população portuguesa**Resumo**

Introdução: A miocardiopatia hipertrófica sarcomérica (MH) tem expressão fenotípica heterogénea, sendo a morte súbita cardíaca a mais temida. O diagnóstico genético é fundamental para identificar os indivíduos em risco em cada família. O perfil genético da doença é desconhecido na população portuguesa.

População e métodos: Estudaram-se geneticamente 77 doentes-índice com MH, não-relacionados, pesquisando-se, por PCR e sequenciação, mutações nos genes *MYBPC3*, *MYH7*, *TNNT2*, *TNNI3* e *MYL2*. Efetuou-se análise de co-segregação familiar na maioria dos doentes.

Resultados: Identificaram-se 34 mutações diferentes em 41 doentes-índice (53%), 71% com MH familiar. O gene mais frequentemente envolvido foi o *MYBPC3* (66%), identificando-se 22 mutações diferentes (8 novas) em 27 doentes-índice. Seguiram-se os genes *MYH7* (22%), *TNNT2* (12%) e *TNNI3* (2,6%). Em 3 doentes (7%) identificaram-se 2 mutações nos genes *MYBPC3* e/ou *MYH7*. Estudaram-se também 276 familiares detetando-se, em média, mais 3 indivíduos em risco, em cada *pedigree* com MH familiar.

Conclusões: Foram identificadas mutações associadas a MH maioritariamente na doença familiar, reforçando a ideia corrente de as formas esporádicas estarem associadas a genes raramente estudados. A maioria das mutações é privada de cada família. O gene *MYBPC3* é o mais frequentemente afetado. As mutações neste gene e no gene *MYH7* são responsáveis pela maioria das situações de MH. Podem existir mutações múltiplas nestes genes, sendo mandatório o seu rastreio. A identificação de mutações novas aconselha a rastrear sistematicamente todas as regiões codificadoras. O estudo genético na MH permite um diagnóstico mais preciso da doença, determinante para a estratificação do risco e para o aconselhamento genético.

© 2011 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L. Todos os direitos reservados.

Introduction

Sarcomeric hypertrophic cardiomyopathy (HCM) is the most prevalent genetic cardiovascular disease and one of the leading causes of sudden cardiac death, particularly in young people. The disease is defined by the presence of increased ventricular wall thickness or mass in the absence of loading conditions sufficient to cause the observed abnormality.¹ The usual clinical marker of the disease is unexplained ventricular hypertrophy, usually identified on echocardiographic examination. Sarcomeric HCM is associated with mutations in genes encoding sarcomere or sarcomere-related proteins. Several different mutations associated with the disease have been identified in at least 12 genes, the myosin-binding protein C (*MYBPC3*) and beta-myosin heavy chain (*MYH7*) genes being the most common. Mutations in these two genes and also in the cardiac troponin T (*TNNT2*) and cardiac troponin I (*TNNI3*) genes are associated with the disease in up to 62% of unrelated sarcomeric HCM patients in various cohorts around the world.²⁻⁹

The disease has an autosomal dominant pattern of transmission, and its penetrance is variable and age-related. As hypertrophy may develop later in life, the commonly accepted prevalence of 0.2%¹⁰ may be an underestimation. The clinical course of HCM is highly unpredictable and there is a risk of sudden death, particularly in individuals considered to have a high clinical risk profile. The risk for those only genetically affected but with no phenotype (carriers) is not well defined.

Although it is believed that specific gene mutations with distinct functional characteristics may contribute to

different phenotypes and prognosis, for most causal mutations prognostication will be difficult, given their private character in affected families. On the other hand, if it is assumed that the true prognostic value of HCM genetic testing simply relies on a positive test (identification of a pathogenic sarcomeric mutation)⁹ and not on the type or location of a particular mutation, then periodic evaluation for risk stratification is recommended to all genetically affected individuals.

Molecular diagnosis distinguishes between sarcomeric HCM and other hypertrophic heart disorders with distinct clinical courses and prognosis. The correct diagnosis of HCM should therefore be the first step in cases of unexplained left ventricular hypertrophy (LVH). If the genetic test is positive – a causal sarcomeric mutation is found in about 60% of affected individuals² – a diagnosis is made and clinical workup is performed in order to help decision-making, particularly to prevent sudden death. Genetic screening of the family follows (in a cascade approach) to identify other at-risk family members. Absence of the causal mutation in relatives will reassure them, since in this case there is at present considered to be no risk of developing the disease.

In 30–40% of index patients, no mutation-associated disease is identified.¹¹ In these cases, although the prognosis appears to be better,⁹ all first-degree relatives should be considered at risk and serial clinical screening is needed.

HCM is a global disease and genotype profiles regarding HCM-associated mutations have been described for several HCM populations in different countries worldwide.^{4-9,12-15} However, data on the Portuguese population are scarce^{16,17} and the prevalence of the most

commonly involved genes is unknown. The main objective of this paper is to report the mutation profile in a Portuguese cohort of unrelated consecutive patients with sarcomeric HCM, followed at a large referral center.

Methods

Population and clinical data

The study included 77 unrelated Portuguese index patients, most of Caucasian origin, 37 female, 40 male, aged 57 (22–82) years old at the time of genotyping, with a diagnosis of HCM based on major echocardiographic criteria as described elsewhere^{5,18} and defined by maximal end-diastolic left ventricular wall thickness (LVWT) >15 mm. This population had a mean age at diagnosis of 44 (16–79) years and have been followed for a mean of 12.7 (1–35) years. Forty patients had at least 10 years of follow-up and 20 had more than 20 years. Most have been followed in the center; the others were referred for the first time to the center and a new echocardiogram and ECG were then performed.

A total of 314 relatives underwent a detailed clinical evaluation to determine whether HCM had a familial or sporadic character. Genotyping was performed in 276 of them in a cascade approach. A complete clinical assessment was undertaken in all patients, including a detailed family history with a pedigree including at least three generations. All available past exams (from index patients and relatives) were reviewed, including autopsy data on relatives who suffered sudden death. In addition to clinical assessment, a biochemical panel was performed in all index patients to exclude unrecognized muscle or renal involvement.

On the basis of clinical criteria and prior to genetic diagnosis, HCM was initially classified as familial, sporadic or inconclusive. Patients with clinically affected relatives were considered as having familial disease. Criteria for diagnosis of HCM in relatives included a maximal wall thickness on echocardiography >13 mm or the presence of major ECG criteria: LVH (assessed by a Romhilt-Estes score ≥ 4) and/or pathological Q waves, in the absence of any other possible causal condition. When HCM could not be clinically diagnosed in relatives (absence of family history and no phenotypic expression on ECG or echocardiogram), HCM was considered to be sporadic or inconclusive (if ≤ 2 relatives were available for study). In addition, if the genetic testing detected a sequence variant considered pathogenic in the index patient and also in other family members (even with a negative phenotype), the disease was classified as familial.

Molecular analysis

After informed consent for genotyping was obtained, systematic mutation screening was performed in all patients in the following sarcomeric genes: *MYBPC3*, *MYH7*, *TNNT2*, *TNNI3* and the regulatory myosin light chain (*MYL2*) gene. Genomic DNA was extracted from 10 ml of peripheral whole blood using standard techniques. Intronic sets of oligonucleotide primers were designed according to the published genomic sequences of the genes. All exon–intron boundaries were amplified. Mutation screening was performed by PCR followed by direct sequencing on an ABI 3100 DNA sequencer,

using the BigDye terminator mix (Applied Biosystems, Lisbon, Portugal).

The first two genes screened were *MYBPC3* and *MYH7*, the two most frequently described as involved in HCM. But even when a mutation was found in one or both of these genes, screening in the other genes proceeded due to the reported frequency of multiple mutations (in the same or in different genes) and their possible impact on prognosis.⁹ When a previously unreported sequence variant (mutation databases: <http://genepath.med.harvard.edu> and <http://www.hgmd.org/>) was identified in the index patient and was considered a possible pathogenic mutation, available first-degree relatives were tested for the identified variant in order to analyze cosegregation with the disease in the family. Except for nonsense and frameshift mutations due to short insertions or deletions and splice site mutations, a missense variant was considered pathogenic when: (1) it affected an amino acid conserved among species; (2) it was absent in another 100 samples; (3) it cosegregated with the disease in the family. For analysis of amino acid conservation we used the *in silico* sequence alignment program Homologene (<http://www.ncbi.nlm.nih.gov/homologene>). Further, to estimate the functional consequences of the novel identified missense mutations we analyzed these variations with the evolutionary model program SNPs&GO (<http://snps-and-go.biocomp.unibo.it>).¹⁹ This in-silicon program takes into account information derived from protein sequence, protein sequence profile and protein function. For each predicted effect the program determines a reliability index (RI) of the prediction, from 0 (unreliable) to 10 (reliable).

The mutation nomenclature was based on protein reference sequences: MIM NP_000247 for *MYBPC3*, MIM NP_000248.1 for *MYH7*, MIM NP_001001430.1 for *TNNT2*, MIM NP_000354 for *TNNI3* and NP_000423.2 for *MYL2*.

If no mutation was identified in the five genes studied, index patients with sporadic or inconclusive disease were additionally tested for Anderson-Fabry disease (genetic screening of the *GLA* gene) considering that, although rare, this disease may be expressed in an entirely or predominantly cardiac phenotype.

Statistical analysis

Clinical and genetic data were presented as total number or as frequency and percentage. Mean values \pm standard deviation are expressed when comparing groups. Differences between groups were compared using the Student's t-test or analysis of variance. Fisher's exact test was used for comparing proportions. A p value of <0.05 was considered significant for all analyses.

Results

Study population

The clinical data of the cohort under study are shown in Table 1.

At the time of genetic testing, all but five patients had predominantly septal hypertrophy, although in many patients other ventricular walls were also involved, with

Table 1 Clinical features of HCM index patients (n = 77). Comparison of familial, sporadic and inconclusive disease.

	Total probands (n = 77)	(a) Familial (n = 41) ^a	(b) Sporadic (n = 16) ^a	(c) Inconclusive (n = 20) ^a	p ^b
<i>Gender</i>					
Male (n)	40	20	9	11	–
Female (n)	37	21	7	9	–
<i>Age (years)</i>	57 (22–82)	56 (28–81)	64 (22–82)	54 (23–78)	0.34
<i>Age (years) at clinical diagnosis</i>	44 (16–79)	39 (19–72)	52 (19–79)	47 (16–77)	0.005
<i>Follow-up (years)^c</i>	12.7 (1–35)	15.85 (1–31)	11.6 (1–35)	7.3 (1–26)	0.003
<i>Maximal wall thickness (mm)^d</i>	23	23	22	23	0.68
<i>OB at rest (>30 mmHg) (n)^d</i>	24 (31%)	14 (34%)	2 (12.5%)	8 (40%)	0.63
<i>Family history of sudden death (n)</i>	28 (36%)	21 (51%)	4 (25%)	3 (15%)	0.005
<i>Atrial fibrillation (n)</i>	21 (27%)	15 (37%)	2 (12.5%)	4 (20%)	0.07
<i>Symptoms (n)</i>	62 (80%)	33 (80%)	13 (81%)	16 (80%)	0.99
<i>Treatment (n)</i>					
Pharmacological	67 (87%)	33 (80%)	15 (94%)	19 (95%)	0.09
Devices (pacemaker/ICD)	16 (21%)	12 (29%)	1 (6%)	3 (15%)	0.09
Myectomy	2 (2.6%)	1	0	1	–

HCM: hypertrophic cardiomyopathy; OB: obstruction (outflow gradient) at rest measured by Doppler echocardiography; ICD: implantable cardioverter-defibrillator.

^a See text for details

^b Comparison between familial cases (a) and sporadic plus inconclusive cases (b + c).

^c Time of clinical follow-up since the first clinical evidence of disease.

^d At the time of genetic testing.

35 patients showing diffuse LVH. In five patients hypertrophy was predominantly or exclusively apical. Most index patients also had major ECG criteria for HCM.

On the basis of phenotype/genotype data (on average four individuals studied in each pedigree), disease was confirmed as familial in 41 cases (53%) and considered sporadic in 16 (21%). In 20 (26%) index patients no conclusions were possible (small families or no relatives available for study) (Table 2).

Cross-comparison between familial and sporadic or inconclusive HCM showed no differences in probands regarding degree of ventricular hypertrophy, presence of obstruction or symptoms or need for pharmacological treatment or device implantation. But familial cases had been diagnosed at a younger age and more frequently had a family history of premature sudden death (Table 1).

No patient had clinical involvement other than of the heart. Muscle enzymes and renal function were also normal in all index patients.

Sarcomeric mutations

Sarcomeric mutations were identified in 41 (53%) out of 77 index patients (Tables 2 and 3), more frequently in familial HCM with 29 out of 41 patients (71%) having a positive genotype (genotype+).

Considering the population with identified mutations, *MYBPC3* was the most commonly involved gene, with 27 out of 41 patients harboring mutations in this gene (66% of genotype+ patients). Mutations in *MYH7* were identified in nine patients (22%), *TNNT2* mutations in five patients (12%) and *TNNI3* mutations in two patients. In total, mutations in *MYBPC3* and/or *MYH7* were found in 83% (34 out of

41 patients) with a positive genotype. Double or compound heterozygosity was identified in three patients (7%): two patients had one mutation in *MYH7* and another in *MYBPC3*, and one had two mutations in *MYBPC3* (Tables 4–6). No mutations were found in *MYL2*.

No patient with no identified mutations in sarcomeric genes had Anderson-Fabry disease.

No differences were observed between index patients with or without identified mutations in terms of gender, age, time of follow-up, morbidity (symptoms, atrial fibrillation, hospitalizations during follow-up or need for device implantation) or family history of sudden death. However, probands with identified mutations were younger at the time of diagnosis and had more severe septal hypertrophy (at diagnosis and after follow-up) (Table 7).

Spectrum of mutations

The spectrum of identified mutations is described in Tables 4–6.

MYBPC3

Twenty-two different mutations were identified in *MYBPC3* in 27 probands (Table 4). Fourteen mutations were missense (seven novel). The other mutations included three nonsense, two frameshift and three intronic mutations (one also novel). The novel and multiple mutations are discussed separately (see below).

Fourteen different mutations already reported as pathogenic were identified in 18 unrelated probands. Most mutations were private, but identical mutations were detected in four unrelated pedigrees. The R495Q mutation was found in three unrelated probands (F43, F81 and F93),

Table 2 Analysis of clinical and genetic studies performed in probands and their relatives.

Probands (n)	G+ probands (n) (%)	Number of clinically studied relatives	Number of phenotypic+ relatives (%)	Number of genetically studied relatives (%)	Number of genotype+ relatives (%)	G+/Ph+ (carriers) (n)	G+/Ph- (carriers) (n)
Total	77	314 (41/proband)	148 (47%)	276 (3.6/proband)	114 (41.3%)	89	25
Familial	41 (53%)	239 (6/proband)	112	213 (6/proband)	102	77	25
Sporadic	16 (21%)	48 (3/proband)	16	39 (2.4/proband)	3	3	0
Inconclusive	20 (26%)	27 (1.3/proband)	20	24 (1.2/proband)	9	9	0

G+: patients with identified mutation; Ph+: patients with HCM phenotype; Ph-: patients with no HCM phenotype.

two with familial HCM and one with inconclusive HCM. The R943X mutation was identified in two probands (F3 – familial HCM; F40 – inconclusive). The N1023KfsX28 mutation was found in two unrelated probands (F8 and F27, both with familial HCM), and the E619K mutation was found in two unrelated probands (F11 and F75, both with familial HCM). The latter two probands demonstrated complex genetic status, with compound heterozygosity in F11 (two different mutations in *MYBPC3*) and double heterozygosity in F75 (one mutation in *MYBPC3* and one in *MYH7*) – see ‘‘Multiple mutations’’ below.

For cosegregation analysis in the overall population of probands with identified mutations in the *MYBPC3* gene, 105 additional relatives were clinically screened and 82 were genetically tested. Familial disease was diagnosed in 19 out of 27 pedigrees. The other eight probands were considered to have either sporadic or inconclusive disease.

MYH7

In this gene, seven different mutations were identified in nine unrelated probands (Table 5). All seven had already been described as associated with HCM.^{5,6,20-29} The missense mutation I263T was identified in three unrelated patients. In two, disease is familial (F1 and F2), with 19 individuals studied in each family and cosegregation with the disease in both. Besides the I263T mutation, another mutation (S928L in *MYBPC3*, novel) was also identified in the first family (F1, double heterozygosity) with unknown functional consequences. The other proband with the I263T mutation (F42) was the only individual studied in his pedigree and was thus considered to have an inconclusive type of disease.

The other six mutations were identified in one proband each. Four of these missense mutations are associated with familial HCM – V320M, R663H, E924K, and E1356K – with 17 relatives studied in total and demonstrated cosegregation with the HCM phenotype in each family. The R663H mutation (familial disease) coexisted with another mutation (E619K) in *MYBPC3* (double heterozygosity).

Two mutations were considered to be associated with either sporadic HCM (K847del) or inconclusive disease (A797T) due to the fact that few relatives were available for study.

TNNT2

Three different mutations were identified in five probands (Table 6). All mutations were previously reported as pathogenic.^{5,30-32}

The N271I missense mutation was identified in one patient and proved to be familial (13 relatives studied). The R278C missense mutation was identified in a small family with a mother and daughter both affected. There was a family history of premature (aged <50 years) sudden death in a first-degree relative. The nonsense W287X mutation was identified in three unrelated probands, two of them with familial disease (cosegregation with the disease in each family). In the case of the other proband, no other relatives were available for study and the familial character was considered inconclusive.

Table 3 HCM probands: genotype status (77 index patients).

	Cases with mutations (n) (%)	<i>MYBPC3</i> (n) ^a	<i>MYH7</i> (n) ^a	<i>TNNT2</i> (n) ^a	<i>TNNI3</i> (n) ^a	<i>MYL2</i> (n) ^a
Total HCM index patients (n = 77)	41 (53%)	27 (65.8%) ^b	9 (22%) ^b	5 (12%)	2 (4.9%)	0
Familial HCM (n = 41)	29 (71%)→	19 (66%)	6 (21%)	4 (14%)	2 (7%)	0
Sporadic HCM (n = 16)	3 (19%)→	2 (67%)	1 (33%)	0	0	0
Inconclusive HCM (n = 20)	9 (45%)→	6 (67%)	2 (22%)	1 (11%)	0	0

HCM: hypertrophic cardiomyopathy.

^a Number of index patients with mutations in each of the five genes screened; 25 patients only have mutations in *MYBPC3* and seven patients only have mutations in *MYH7*.

^b Two patients have mutations in both genes (double heterozygosity); one patient has two mutations in *MYBPC3* (compound heterozygosity).

TNNI3

Two different missense mutations – A157V and S199N – were identified in this gene (Table 6), in two unrelated patients, both with familial disease and with more than 15 years of follow-up. Both mutations had been reported as pathogenic.^{5,33,34}

Multiple mutations

In three probands (4% of the overall population and 7% of genotype-positive patients), two mutations were found (Tables 4 and 5). All three patients have familial HCM. One carries two mutations in *MYBPC3* (compound heterozygosity): R502Q and E619K – both previously described. The other two patients showed double heterozygosity: E619K in *MYBPC3* with R663H in *MYH7* in one patient (both mutations previously described); and I263T in *MYH7* and S928L in *MYBPC3* in the other. The latter mutation in *MYBPC3* is novel and although its RI is 8 its functional consequences are still unknown.

A comparison was performed regarding clinical characteristics between index patients with single mutations in the *MYH7*, *MYBPC3* and *TNNT2* plus *TNNI3* genes (Table 8). Patients with double mutations were excluded from this analysis. No differences were observed regarding age, degree of LVH at time of diagnosis, length of follow-up, morbidity or family history of sudden death. However, an association was found between the affected gene and maximal wall thickness, with higher values in patients with identified mutations in *MYBPC3* than in patients with mutations in the other genes (after the same follow-up period).

Novel mutations

Eight novel variants were identified in the study population (Table 4), all in the *MYBPC3* gene.

Seven of the mutations were missense. All were detected in coding regions of the gene. The affected amino acids are conserved in various species and the mutations were not detected in any others of 100 samples. Their effects predicted by the SNPs&GO program led them to be considered as disease-related, with an RI of 7–10. An RI of 7 or 8 was found for only one mutation each (see Table 4 and below), the other five novel mutations having an RI of 9 or 10. All

of these novel mutations were found in only one proband, except V783L, which was identified in two index patients (one with familial disease).

The seven index patients with these novel missense mutations were followed for a mean of 15 (1–30) years before genotyping and had a mean maximal wall thickness of 26 (21–32) mm at the time of genotyping. Six of them (86%) showed considerable HCM-related morbidity during follow-up – hospitalization or need for devices or surgery (myectomy or mitral prosthesis) – and three have a family history of premature sudden death. In total, 40 relatives were studied for cosegregation analysis. From these cosegregation studies, five of the seven novel mutations were associated with familial disease. Nevertheless, as mentioned above, the pathogenicity of the S928L mutation (with an RI of 8) is unclear, as it occurred together with another disease-related mutation in the pedigree.

Concerning the other two of the seven novel missense mutations, Q921L was identified in a proband considered to have sporadic HCM (RI for this mutation was 7). The G1195V mutation (RI of 9) was detected in one proband with HCM and with a history of premature sudden cardiac death in a first-degree relative. No further relatives are available for study, and thus the sporadic or familial character of HCM in these cases was considered inconclusive.

A novel intronic variant (c.506-17C>T) in *MYBPC3* was also identified in a patient with obstructive HCM and severe LVH. Familial studies are proceeding, but the significance of this new variant is for the moment unknown.

Additional results on familial, sporadic or inconclusive disease

Familial HCM

Concerning the 41 unrelated probands with familial HCM, mutations were identified in 29 (71%). Clinical screening was performed in 239 relatives and genetic screening in 213 (on average six individuals were studied in each family) (Table 2).

Clinically, 112 individuals out of 239 (47%) had HCM; genetically, 102 out of 213 (47%) had identified mutations. It should be noted that not all clinically affected individuals were genetically screened but those who were had

Table 4 Spectrum of mutations in *MYBPC3* gene (27 index patients).

Exon/intron	Nucleotide change	Coding effect	Consequence	Novel mutation	SNPs&GO – RI (only for novel mutations)	Index patients	Patient ID	Comments
Intron 4	c.506-17C>T	–	Splice site	Yes	–	1	F80	–
Exon 5	c.481C>T	P161S	Missense	No	–	1	F9	–
Exon 7	c.817C>T	R273C	Missense	Yes	Disease related – RI: 9	1	F63	–
Exon 11	c.977G>A	R326Q	Missense	No	–	1	F74	–
Intron 13	c.1227-13G>A	–	Splice site	No	–	1	F76	–
Intron 17	c.1790+1G>C	–	Splice site	No	–	1	F15	–
Exon 18	c.1484G>A	R495Q	Missense	No	–	3	F43, F81, F93	–
Exon 18	c.1505G>A	R502Q	Missense	No	–	1	F11	Compound heterozygosity with E619K (<i>MYBPC3</i>)
Exon 18	c.1730G>A	W577X	Nonsense	No	–	1	F26	–
Exon 18	c.1800delA	K600NfsX2	Frameshift	No	–	1	F44	–
Exon 18	c.1828G>A	D610N	Missense	Yes	Disease related – RI: 10	1	F72	–
Exon 18	c.1855G>A	E619K	Missense	No	–	2	F11, F75	Double heterozygosity with R663H (<i>MYH7</i>)
Exon 23	c.2347G>T	V783L	Missense	Yes	Disease related – RI: 9	1	F34, F78	–
Exon 25	c.2670G>A	W890X	Nonsense	No	–	1	F82	–
Exon 25	c.2686G>A	V896M	Missense	No	–	1	F39	–
Exon 26	c.2762A>T	Q921L	Missense	Yes	Disease related – RI: 7	1	F14	–
Exon 26	c.2783C>T	S928L	Missense	Yes	Disease related – RI: 8	1	F1	Double heterozygosity with I263T (<i>MYH7</i>)
Exon 26	c.2827C>T	R943X	Nonsense	No	–	2	F3, F40	–
Exon 28	c.3065G>C	R1022P	Missense	Yes	Disease related – RI: 10	1	F23	–
Exon 28	c.3069dupA	N1023KfsX28	Frameshift	No	–	2	F8, F27	–
Exon 31	c.3584G>T	G1195V	Missense	Yes	Disease related – RI: 9	1	F64	–
Exon 31	c.3617G>A	G1206D	Missense	No	–	1	F96	–

ID: patient identification; SNP&GO – RI: reliability index of the predicted effect (see text for details).

Table 5 Spectrum of mutations in *MYH7* gene (9 index patients).

Exon/intron	Nucleotide change	Coding effect	Consequence	Index patients	Patient ID	Comments
9	c.788T>C	I263T	Missense	3	F1; F2; F42	Associated with S928L (<i>MYBPC3</i>)
11	c.958G>A	V320M	Missense	1	F50	
18	c.1988G>A	R663H	Missense	1	F75	Associated with E619K (<i>MYBPC3</i>)
21	c.2389G>A	A797T	Missense	1	F88	
22	c.2539_2541delAAG	K847del	In-frame deletion	1	F57	
23	c.2770G>A	E924K	Missense	1	F10	
30	c.4066G>A	E1356K	Missense	1	F28	

ID: patient identification.

Table 6 Spectrum of mutations in *TNNT2* and *TNNI3* genes.

Gene, exon	Nucleotide change	Coding effect	Consequence	Index patients (n)	Patient ID
<i>TNNT2</i>					
15	c.812A>T	N271I	Missense	1	F41
16	c.832C>T	R278C	Missense	1	F66
16	c.860G>A	W287X	Nonsense	3	F56; F69; F94
<i>TNNI3</i>					
7	c.470C>T	A157V	Missense	1	F17
8	c.596G>A	S199N	Missense	1	F20

ID: patient identification.

a positive genotype (77 relatives genotype+/phenotype+). Additionally, 25 carriers were identified.

Sporadic HCM

Sixteen index patients were considered to have sporadic disease (21% of the study cohort). A mutation was identified in three (7% of patients with a positive genotype). The novel variant Q921L in *MYBPC3* was found in a patient with diffuse LVH and a MWT of 31 mm (septal), subaortic obstruction and

severe heart failure with preserved systolic function (no living first-degree relatives). The c.1790+1G>C mutation (not novel) was also identified in *MYBPC3* in a young woman with LVH and clinically normal first-degree relatives. The previously described K847E mutation in *MYH7* was found in one patient. A total of 48 relatives of pedigrees with sporadic HCM were clinically screened (about three in each family) and in 39 genetic testing was also performed. None had a clinical phenotype or a positive genetic test.

Table 7 Comparison between index patients with and without identified mutations.

	G+ probands (n=41)	G- probands (n=36)	p
<i>Age at HCM diagnosis</i>	40.0 ± 18.7	48.1 ± 13.3	0.03
<i>LVH at diagnosis</i>	20.6 ± 4.56	17.6 ± 3.21	0.002
<i>Familial SD (n) (%)</i>	18 (43.9%)	10 (27.8%)	0.16
<i>Time of follow-up (years)</i>	13 ± 10.3	12.4 ± 9.6	0.8
Symptoms (n) (%)	33 (80.5%)	29 (80.6%)	0.99
Need for drug therapy (n) (%)	36 (87.8%)	31 (86.1%)	0.99
Devices (PM/ICD) (n) (%)	11 (26.8%)	5 (13.9%)	0.26
AF (n) (%)	14 (34.2%)	7 (19.4%)	0.20
<i>Data at genotyping</i>			
Age	53.7 ± 18.5	60.3 ± 12.9	0.08
MWT (mm)	24.2 ± 4.23	21 ± 4.66	0.002
Diffuse LVH (n)	22 (53.7%)	13 (36%)	0.17
OB (n) (%)	14 (34.2%)	10 (27.8%)	0.16

AF: atrial fibrillation; HCM: hypertrophic cardiomyopathy; ICD: implantable cardioverter-defibrillator; genotype-positive (+): index patients with identified mutations; genotype negative (-): index patients without identified mutations; LVH: left ventricular hypertrophy; MWT: maximal wall thickness; OB: presence of obstruction; PM: pacemaker; SD: sudden death.

Table 8 Comparison between index patients with mutations in different genes.

Gene affected (n patients)	<i>MYH7</i> (n = 8)	<i>MYBPC3</i> (n = 25)	<i>TNNT2</i> plus <i>TNNI3</i> (n = 7)	p
Age at HCM diagnosis	38.6 ± 20.9	40.7 ± 19.6	38.6 ± 16.5	0.95
LVH at diagnosis	17.9 ± 4.41	21.6 ± 4.73	19.3 ± 3.30	0.12
Familial SD (n) (%)	4 (50%)	11 (44%)	3 (42.9%)	0.99
Time of follow-up (years)	19.6 ± 12.34	11.5 ± 9.25	8.29 ± 6.85	0.06
Symptoms (n) (%)	7 (87.5%)	21 (84%)	4 (57%)	0.30
Need for drug therapy (n) (%)	8 (100%)	22 (88%)	5 (71.4%)	0.17
Devices (PM/ICD) (n) (%)	2 (25%)	7 (28%)	1 (14.3%)	0.88
AF (n) (%)	1 (12.5%)	11 (44%)	1 (14.3%)	0.18
Data at genotyping				
Age	58.1 ± 17.8	53.4 ± 19.3	46.9 ± 16.7	0.51
MWT (mm)	22.9 ± 5.33	25.6 ± 6.74	21 ± 2.83	0.02
Diffuse LVH (n)	4 (50%)	15 (60%)	2 (28.6%)	0.33
OB (n) (%)	1 (12.5%)	10 (40%)	3 (42.9%)	0.33

Patients with more than one mutation were excluded from the comparison. AF: atrial fibrillation; HCM: hypertrophic cardiomyopathy; ICD: implantable cardioverter-defibrillator; LVH: left ventricular hypertrophy; MWT: maximal wall thickness; OB: presence of obstruction; PM: pacemaker; SD: sudden death.

Inconclusive HCM

In 20 index patients, no conclusion regarding the familial or sporadic character of HCM could be drawn due to the small number of relatives studied. However, a mutation was identified in nine of these 20 index patients (22% of the population with a positive genotype). Of these, six mutations were already described as pathogenic and three were novel.

Concerning the six previously described mutations (*MYBPC3*: R943ter, R326Q, R495Q; *MYH7*: I263T, A797T; *TNNT2*: Trp287X), four were also identified as causing familial HCM in other probands of our population: R943X (*MYBPC3*) in one pedigree; R495Q (*MYBPC3*) in two pedigrees; I263T (*MYH7*) in two pedigrees (see above); and W287X (*TNNT2*) in two other pedigrees. Thus four cases of inconclusive HCM might be in fact familial, although an insufficient number of relatives were available for study. The other two previously reported mutations – R326Q (*MYBPC3*) and A797T (*MYH7*) – were only found in two unrelated probands and were also considered to be inconclusive cases.

Of the three novel mutations in *MYBPC3* in patients with inconclusive disease, the G1195V mutation was detected in only one patient (see above) with no relatives available for study. The V783L mutation – with an RI of 9 – was first found in one proband with disease diagnosed 36 years previously and followed since then. However, the same mutation was also identified in a case of familial HCM in our cohort, with several relatives studied and cosegregation demonstrated with the disease in that family. The novel variant in intron 4 (c.506-17C>T) was identified in one proband. The pathogenicity of this variant is uncertain.

Discussion

The present study reports the frequency and profile of single and multiple mutations in a Portuguese cohort of unrelated HCM index patients, most with an established diagnosis for many years (mean follow-up 12.7 years). The entire coding regions of five sarcomeric genes were screened

for alterations in order to identify all described and as yet unreported mutations. Our results demonstrated an overall mutation detection rate of 53%. This is in agreement with previously reported data in other population studies.^{4-6,8,9,12,15} All mutations in our cohort were identified in the four genes most commonly associated with HCM (*MYBPC3*, *MYH7*, *TNNT2* and *TNNI3*). Familial HCM showed the highest rate of mutations, comprising 71% of the population with a positive genotype.

In a recent study that included only HCM index patients genotyped for these four genes,¹⁵ a higher rate of mutations in familial disease (64%) was found in a French population compared to sporadic (29%) or inconclusive disease (46%). These data corroborate previously published studies in the French population showing a 70% frequency of sarcomeric mutations in familial HCM.⁵ In our cohort, only 7% (three out of 16 patients) of sporadic HCM and 22% of patients (9 out of 20) with inconclusive disease had an identified mutation.

Differences concerning sporadic or inconclusive disease may be explained by differences in the populations studied, as is always the case with HCM. The number of relatives available for studying cosegregation with the disease in each family is highly variable in different published series, as is the information on a diagnosis of HCM in relatives. Additionally, a different number of genes are screened in each population studied. Studies that include predominantly familial HCM have a high rate of genotype-positive patients,¹² as is the case with our study. Sporadic HCM was found in only 21% of our cohort; it is less frequent than familial HCM and is diagnosed later.

Our findings show that many of the inconclusive HCM cases are in fact familial. The study of as many relatives as possible in each family should be the goal in HCM genetic population studies.

In 36 patients (46%) – including 29% of those with familial HCM – no mutations were identified in the five genes screened.

We are aware that screening only five sarcomeric genes may have missed some genotype cases in other genes,

although most myofilament mutations associated with HCM are usually identified in the four genes mutated in our population. No mutations were found in *MYL2* in our population, and the reported mean frequency of mutations in *TPM1* (encoding α -tropomyosin), *MYL3* (myosin essential light chain) and *ACTC* (encoding α -actin) is very low, 1.21%, 0.11% and 0.49%, respectively.¹² It is commonly thought that since HCM is a genetically heterogeneous disease, patients with HCM and no identified mutations in the known myofilament coding genes may in fact have mutations in unexplored regions of these genes. Alternatively mutations may exist in novel myofilament encoding genes (like titin, muscle LIM protein, telethonin, myozenin 2 or vinculin) or in other HCM-susceptibility genes that were not screened in our cohort.

Some differences were observed in our population between patients with and without myofilament identified mutations. Patients with a positive genotype were younger at the time of diagnosis and showed more severe septal hypertrophy (at diagnosis and after the same follow-up time). The implications of these findings need further study.

Mutations in *MYBPC3* were the most prevalent cause of HCM in our cohort, with 35% of probands affected. The frequency of mutations in *MYBPC3* has been reported as ranging from 14% to 26% in HCM.^{12,15} A recent study of an Italian cohort including 203 unrelated HCM patients⁹ found that 34% had mutations in *MYBPC3*, a similar frequency to ours. Although defining the pathogenicity of mutations in *MYBPC3* (especially for missense mutations) is particularly challenging, the criteria applied in our study for the novel variants identified support the idea that most of the missense variants identified are indeed pathogenic and their effects are not overestimated.

The prevalence of patients with mutations in the *MYH7* gene was 11.7%. Findings in other studies ranged from 2.8% to 25%.¹² The number of patients with mutations in *MYH7* in our study is unlikely to be underestimated as the entire coding sequence of the gene was analyzed. Mutations in this gene and in *MYBPC3* were found in 87% of genotype-positive patients, a frequency close to that reported in other studies.^{5,9,15}

The *TNNT2* gene was affected in 6.5% of HCM probands (12% of genotype-positive patients). Mutations in this gene are the most commonly involved in thin filament-HCM, with reported values for affected probands ranging from 0% to 6.67%.^{22,35} Mutations in the *TNNI3* gene were also found in 2.6% of HCM patients (4.9% of those with identified mutations), in agreement with previously reported rates (ranging from 0% to 6.5%).^{12,15}

Multiple mutations were detected in 7% of index patients with a positive genotype. This finding is in line with previously published studies^{4,5,7,9} and indicates that once a single sarcomeric mutation is identified in a patient a continued search for other mutations is necessary, at least in *MYBPC3* and *MYH7*, the two genes most commonly associated with sarcomeric HCM.

Comparison of clinical data of patients with single mutations in different genes showed no significant differences except for a higher degree of hypertrophy after follow-up in patients with *MYBPC3* gene mutations. The possible interpretations of this finding are beyond the scope of this study, since the rate of different private mutations in this gene was very high and the specific functional effect of each mutation

on disease expression is unknown. Furthermore, it is not the purpose of this study to establish associations between specific genotypes and phenotypes in HCM or to put forward considerations about individual prognosis.

A genetic diagnosis establishing a causal relationship with HCM is important for several reasons. First, it identifies affected individuals (excluding other less prevalent genetic causes of cardiac hypertrophy with different outcomes). Second, it enables identification of family members with a positive genotype at risk of developing HCM who require rigorous and serial follow-up for risk stratification. Third, knowledge of the genetic cause of HCM not only may in the near future help direct treatment strategies in already clinically affected patients³⁶ but also, within families with different mutations, the identification of carriers (in a preclinical state) may enable preventive interventions to limit disease development, a possibility that is already under study (<http://clinicaltrials.gov/ct2/show/record/NCT00319982>). Additionally genetic study should be performed to reassure genotype-negative family members.

Conclusions

The molecular screening of five sarcomeric genes associated with HCM in a Portuguese population enabled a genetic diagnosis in 53% of a consecutive cohort of unrelated patients. The highest yield was observed in familial HCM (71%). The most commonly mutated gene was *MYBPC3*, but since mutations in this gene and in *MYH7* account for most genotype-positive patients and more than one mutation was found in 4% of HCM patients, both genes should be systematically screened as a first genetic approach by testing the entire coding regions of these genes. Private mutations were the rule and novel mutations were a frequent finding, illustrating the difficulty of making genotype-phenotype correlations in HCM on an individual basis for each mutation. Independently of the gene affected, genotype-positive patients were younger at the time of diagnosis and had more severe hypertrophy than patients with a negative genotype, although the significance of these findings and their impact on prognosis needs further evaluation. The identification of a positive genotype in probands led to confirmation of the disease in a substantial number of relatives, including 25 carriers (genetically positive, preclinical state) with implications for follow-up, risk stratification and genetic counseling.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J*. 2008;29:270–6.
2. Richard P, Villard E, Charron P, Isnard R. The genetic bases of cardiomyopathies. *J Am Coll Cardiol*. 2006;48:A79–89.

3. Bos JM, Ommen SR, Ackerman MJ. Genetics of hypertrophic cardiomyopathy: one, two, or more diseases? *Curr Opin Cardiol*. 2007;22:193–9.
4. Erdmann J, Daehmlow S., Wischke S, Senyuva M, Werner U, Raible J, et al. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. *Clin Genet*. 2003;64:339–49.
5. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, et al.; EUROGENE Heart Failure Project. Hypertrophic cardiomyopathy distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. *Circulation*. 2003;107:2227–32.
6. Van Driest SL, Jaeger MA, Ommen SR, Will ML, Gersh BJ, Tajik AJ, et al. Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2004;44:602–10.
7. Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ, et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2004;44:1903–10.
8. Morita H, Larson MG, Barr SC, Vasan RS, O'Donnell CJ, Hirschhorn JN, et al. Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham heart study. *Circulation*. 2006;113:2697–705.
9. Olivetto L, Girolami F, Ackerman MJ, Nistri S, Bos JM, Zachara E, et al. Myofibrillar protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. *Mayo Clin Proc*. 2008;83:630–8.
10. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults. *Circulation*. 1995;92:785–9.
11. Marian AJ, Roberts R. To screen or not is not the question – it is when and how to screen. *Circulation*. 2003;107:2171–4.
12. Van Driest SL, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Sarcomeric genotyping in hypertrophic cardiomyopathy. *Mayo Clin Proc*. 2005;80:463–9.
13. Girolami F, Olivetto I, Passerini I, Zachara E, Nistri S, Re F, et al. A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. *J Cardiovasc Med (Hagerstown)*. 2006;7:601–7.
14. Garcia-Castro M, Coto E, Reguero JR, Berrazueta JR, Alvarez V, Alonso B, et al. Mutations in sarcomeric genes MYH7, MYBPC3, TNNT2, TNNT3 and TPM1 in patients with hypertrophic cardiomyopathy. *Rev Esp Cardiol*. 2009;62:48–56.
15. Millat G, Bouvagnet P, Chevalier P, Dauphin C, Jouk PS, Da Costa A, et al. Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. *Eur J Med Genet*. 2010;53:261–7.
16. Cardim N, Perrot A, Santos S, Morgado P, Pádua M, Ferreira S, et al. Hypertrophic cardiomyopathy in a Portuguese population: mutations in the myosin-binding protein C gene. *Rev Port Cardiol*. 2005;24:1463–76.
17. Brito D, Madeira H. Malignant mutations in hypertrophic cardiomyopathy: fact or fancy? *Rev Port Cardiol*. 2005;24:1137–46.
18. Charron P, Dubourg O, Desnos M, Isnard R, Hagege A, Millaire A, et al. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. *Circulation*. 1997;96:214–9.
19. Calabrese R, Capriotti E, Fariselli P, Martelli PL, Casadio R. Functional annotations improve the predictive score of human disease related mutations in proteins. *Human Mutat*. 2009;30:1237–44.
20. Tesson F, Dufour C, Moolman JC, Carrier L, al-Mahdawi S, Chojnowska L, et al. The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. *J Mol Cell Cardiol*. 1997;29:831–8.
21. Brito D, Richard P, Isnard R, Pipa J, Komajda M, Madeira H. Familial hypertrophic cardiomyopathy: the same mutation, different prognosis. Comparison of two families with a long follow-up. *Rev Port Cardiol*. 2003;22:1445–61.
22. Watkins H, Thierfelder L, Hwang DS, McKenna W, Seidman JG, Seidman CE. Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations. *J Clin Invest*. 1992;90:1666–71.
23. Mörner S, Richard P, Kazzam E, Hellman U, Hainque B, Schwartz K, et al. Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden. *J Mol Cell Cardiol*. 2003;35:841–9.
24. Song L, Zou Y, Wang J, Wang Z, Zhen Y, Lou K, et al. Mutations profile in Chinese patients with hypertrophic cardiomyopathy. *Clin Chim Acta*. 2005;351:209–16.
25. Perrot A, Schmidt-Traub H, Hoffmann B, Prager M, Bit-Avragim N, Rudenko RI, et al. Prevalence of cardiac beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. *J Mol Med*. 2005;83:468–77.
26. Havndrup O, Bundgaard H, Andersen PS, Allan Larsen L, Vuust J, Kjeldsen K, et al. Outcome of clinical versus genetic family screening in hypertrophic cardiomyopathy with focus on cardiac beta-myosin gene mutations. *Cardiovasc Res*. 2003;57:347–57.
27. Moolman JC, Brink PA, Corfield VA. Identification of a novel Ala797Thr mutation in exon 21 of the beta-myosin heavy chain gene in hypertrophic cardiomyopathy. *Hum Mutat*. 1995;6:197–8.
28. Gruver EJ, Fatkin D, Dodds GA, Kisslo J, Maron BJ, Seidman JG, et al. Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation. *Am J Cardiol*. 1999;83:13H–8H.
29. Ingles J, Doolan A, Chiu C, Seidman J, Seidman C, Semsarian C. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. *J Med Genet*. 2005;42:e59.
30. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. *N Engl J Med*. 1995;332:1058–64.
31. Elliott PM, D'Cruz L, McKenna WJ. Late-onset hypertrophic cardiomyopathy caused by a mutation in the cardiac troponin T gene. *N Engl J Med*. 1999;341:1855–6.
32. Theopistou A, Anastasakis A, Miliou A, Rigopoulos A, Toutouzas P, Stefanadis C. Clinical features of hypertrophic cardiomyopathy caused by an Arg278Cys missense mutation in the cardiac troponin T gene. *Am J Cardiol*. 2004;94:246–9.
33. Mogensen J, Murphy RT, Kubo T, Bahl A, Moon JC, Klausen IC, et al. Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2004;44:2315–25.
34. Mogensen J, Klausen IC, Egeblad H. Sudden cardiac death in familial hypertrophic cardiomyopathy is associated with a novel mutation in the troponin I gene. *Circulation*. 1999;100:1–618.
35. Garcia-Castro M, Reguero JR, Batalla A, Díaz-Molina B, González P, Alvarez V, et al. Hypertrophic cardiomyopathy: low frequency of mutations in the beta-myosin heavy chain (MYH7) and cardiac troponin T (TNNT2) genes among Spanish patients. *Clin Chem*. 2003;49:1279–85.
36. Penicka M, Gregor P, Kerekes R, Marek D, Curila K, Krupicka J; Candesartan use in Hypertrophic And Non-obstructive Cardiomyopathy Estate (CHANCE) Study Investigators. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot randomized study. *J Mol Diagn*. 2009;11:35–41.